CMPX Logo

Compass Therapeutics, Inc. (CMPX) 

NASDAQ$2.46
Market Cap
$340.18M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
524 of 924
Rank in Industry
303 of 527

CMPX Insider Trading Activity

CMPX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$00
Sells
$00

Related Transactions

No records found

About Compass Therapeutics, Inc.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product …

Insider Activity of Compass Therapeutics, Inc.

Over the last 12 months, insiders at Compass Therapeutics, Inc. have bought $0 and sold $0 worth of Compass Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Compass Therapeutics, Inc. have bought $19.83M and sold $103,708 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 10,000 shares for transaction amount of $33,700 was made by Schuetz Thomas J. (CHIEF EXECUTIVE OFFICER) on 2023‑03‑10.

List of Insider Buy and Sell Transactions, Compass Therapeutics, Inc.

2023-03-10PurchaseSchuetz Thomas J.CHIEF EXECUTIVE OFFICER
10,000
0.008%
$3.37$33,700-31.33%
2023-02-27PurchaseSchuetz Thomas J.CHIEF EXECUTIVE OFFICER
20,000
0.016%
$3.98$79,600-39.44%
2023-02-15PurchaseSchuetz Thomas J.CHIEF EXECUTIVE OFFICER
20,000
0.0153%
$3.86$77,200-38.69%
2023-01-31PurchaseSchuetz Thomas J.CHIEF EXECUTIVE OFFICER
20,000
0.016%
$4.05$81,000-35.75%
2023-01-24PurchaseSchuetz Thomas J.CHIEF EXECUTIVE OFFICER
20,000
0.0158%
$4.19$83,800-37.29%
2022-11-25SaleBisker-Leib VeredChief Operating Officer
2
<0.0001%
$4.36$9-28.83%
2022-11-23SaleBisker-Leib VeredChief Operating Officer
9,569
0.0088%
$4.30$41,147-30.00%
2022-11-22SaleBisker-Leib VeredChief Operating Officer
14,929
0.0139%
$4.19$62,553-27.27%
2022-11-08PurchaseORBIMED ADVISORS LLCdirector
402,000
0.2887%
$3.21$1.29M-25.18%
2022-11-08PurchaseGORDON CARL Ldirector
402,000
0.2887%
$3.21$1.29M-25.18%
2022-09-07PurchaseSchuetz Thomas J.CHIEF EXECUTIVE OFFICER
15,000
0.0148%
$3.03$45,450+4.92%
2022-09-01PurchaseSchuetz Thomas J.CHIEF EXECUTIVE OFFICER
15,000
0.0145%
$2.83$42,450+10.34%
2022-08-17PurchaseSchuetz Thomas J.CHIEF EXECUTIVE OFFICER
15,000
0.0151%
$3.05$45,750+6.67%
2022-08-10PurchaseSchuetz Thomas J.CHIEF EXECUTIVE OFFICER
15,000
0.0146%
$2.64$39,600+19.40%
2022-08-01PurchaseSchuetz Thomas J.CHIEF EXECUTIVE OFFICER
15,000
0.0145%
$2.58$38,700+21.21%
2022-06-21PurchaseSchuetz Thomas J.CHIEF EXECUTIVE OFFICER
20,000
0.019%
$2.80$56,000+9.25%
2022-06-16PurchaseSchuetz Thomas J.CHIEF EXECUTIVE OFFICER
20,000
0.0188%
$2.34$46,800+28.74%
2022-06-13PurchaseSchuetz Thomas J.CHIEF EXECUTIVE OFFICER
30,000
0.0339%
$2.29$68,700+57.71%
2022-06-06PurchaseSchuetz Thomas J.CHIEF EXECUTIVE OFFICER
30,000
0.0304%
$2.83$84,900+14.08%
2022-06-01PurchaseSchuetz Thomas J.CHIEF EXECUTIVE OFFICER
20,000
0.0206%
$3.03$60,600+8.22%
Total: 35

Insider Historical Profitability

12.91%
ORBIMED ADVISORS LLCdirector
15219994
11.0064%
$37.44M30<0.0001%
GORDON CARL Ldirector
15219994
11.0064%
$37.44M50+26.53%
OrbiMed Genesis GP LLC
14690178
10.6233%
$36.14M20+76.65%
Schuetz Thomas J.CHIEF EXECUTIVE OFFICER
6021873
4.3547%
$14.81M200+7.17%
Sunderland Juliedirector
2502025
1.8094%
$6.15M10

Historical Insider Profitability vs. Competitors

$99,438,720
81
6.74%
$290.44M
$5,911,307
70
-1.38%
$309.77M
$109,415,500
33
18.13%
$353.41M
Compass Therapeutics, Inc.
(CMPX)
$41,446,394
27
12.91%
$340.18M
$24,857,912
21
-35.40%
$287.11M

CMPX Institutional Investors: Active Positions

Increased Positions55+84.62%17M+18.36%
Decreased Positions23-35.38%8M-8.48%
New Positions19New8MNew
Sold Out Positions7Sold Out2MSold Out
Total Postitions97+49.23%101M+9.88%

CMPX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Orbimed Advisors Llc$64,852.0016.2%22.36M00%2024-12-31
Blackstone Inc.$29,073.007.27%10.03M00%2024-12-31
Mpm Bioimpact Llc$24,847.006.21%8.57M+3M+51.86%2024-12-31
Enavate Sciences Gp, Llc$22,586.005.64%7.79M+8MNew2024-12-31
Blackrock, Inc.$19,974.004.99%6.89M+67,163+0.98%2024-12-31
Adage Capital Partners Gp, L.L.C.$17,385.004.34%5.99M-5M-46.14%2024-12-31
Tang Capital Management Llc$17,110.004.28%5.9M+4M+225.43%2024-12-31
Rock Springs Capital Management Lp$16,761.004.19%5.78M+150,336+2.67%2024-12-31
Vanguard Group Inc$13,683.003.42%4.72M+435,008+10.16%2024-12-31
Fmr Llc$11,996.003%4.14M+130+<0.01%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.